Upgrade to SI Premium - Free Trial

Barclays Double Upgrades Celldex Therapeutics (CLDX) to Overweight

April 20, 2026 3:59 AM
Barclays analyst Etzer Darout upgraded Celldex Therapeutics (NASDAQ: CLDX) from Underweight to Overweight with a price target of $45.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Upgrades